利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

122 条记录 (耗时 0.024 秒)

    METHOD OF PREVENTING, MEDICATING AND/OR TREATING HYPOCALCAEMIA OF DOMESTIC MAMMAL
    3.
    发明公开
    METHOD OF PREVENTING, MEDICATING AND/OR TREATING HYPOCALCAEMIA OF DOMESTIC MAMMAL 审中-公开
    用于预防，用药方法和/或治疗有低钙血症PETS

    公开(公告)号：EP1719513A1

    公开(公告)日：2006-11-08

    申请号：EP05710610.6

    申请日：2005-02-17

    申请人： MERCIAN CORPORATION

    发明人： NAITO, Yoshihisa ,  YAMAGISHI, Norio ,  OKURA, Norimoto

    IPC分类号： A61K31/593 ,  A61P3/02 ,  A61P3/14

    CPC分类号： A61K9/0034 ,  A61K31/593

    摘要： The present invention provides a method of preventing, curing, and/or treating hypocalcemia of a domestic mammal, especially, a cow.
    Specifically, the present invention provides a method of administrating a vitamin D derivative to prevent, cure and/or treat hypocalcemia, characterized in that a vitamin D derivative, especially, 1α-hydroxyvitamin D 3 and/or 1.25-dihydroxyvitamin D 3 is transvaginally administered to a domestic mammal.

    摘要翻译： 本发明提供了预防，治疗，和/或治疗家养哺乳动物的低钙血症的方法，特别是爱，牛。 具体而言，本发明提供了施用的维生素D衍生物，以预防，治愈和/或治疗低钙血症的方法，其特征在于在没有维生素D衍生物，爱尤其，1±羟基维生素D 3和/或1.25二羟基维生素D 3是经阴道 给予国内哺乳动物。

    METHOD OF EXAMINING SENSITIVITY OF CANCER CELL TO ANTICANCER AGENT
    4.
    发明公开
    METHOD OF EXAMINING SENSITIVITY OF CANCER CELL TO ANTICANCER AGENT 有权
    VERFAHREN ZUR UNTERSUCHUNG DER EMPFINDLICHKEIT EINER KREBSZELLEGEGENÜBEREINEM ANTIKREBSMITTEL

    公开(公告)号：EP1712642A1

    公开(公告)日：2006-10-18

    申请号：EP05710143.8

    申请日：2005-02-04

    申请人： Eisai R&D Management Co., Ltd. ,  MERCIAN CORPORATION

    发明人： UENAKA, Toshimitsu, Eisai R&D Management Co.,Ltd. ,  IWATA, Masao, Eisai R&D Management Co.,Ltd.

    IPC分类号： C12Q1/68 ,  C12Q1/02 ,  G01N33/48 ,  G01N33/53 ,  A61K31/365 ,  A61K31/496 ,  A61P35/00 ,  C07D407/06

    CPC分类号： C12Q1/6886 ,  A61K31/365 ,  A61K31/496 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5011

    摘要： If a cancer cell sampled from a cancer patient by biopsy or the like can be examined with respect to its expressed molecules to evaluate sensitivity of the cancer cell to the present compound, the present compound can be selectively administered only to the cancer patient who is expected to benefit from antitumor activity of the present compound, thereby to enhance the therapeutic effect and reduce unnecessary adverse effects. Specifically, the characteristics of a cancer cell with respect to "low level expression of pRB", "positive expression of p16" and "high level expression of cyclin E" are demonstrated to be useful as markers for sensitivity of the cancer cell to the present compound. Therefore, these characteristics of a cancer cell can be examined to evaluate previously sensitivity of the cancer cell to the present compound.

    摘要翻译： 如果可以通过活组织检查等从癌症患者取样的癌细胞相对于其表达的分子进行检查，以评估癌细胞对本发明化合物的敏感性，则本发明化合物可以仅选择性地施用于预期的癌症患者 受益于本发明化合物的抗肿瘤活性，从而提高治疗效果并减少不必要的不​​良反应。 具体地说，癌细胞相对于pRB的低水平表达，“p16的阳性表达”和“细胞周期蛋白E的高水平表达”的特征被证明可用作癌细胞对本发明敏感性的标记 复合。 因此，可以检查癌细胞的这些特征，以评估癌细胞对本发明化合物的以前的敏感性。

    PROCESS FOR PRODUCING MACROLIDE COMPOUND
    5.
    发明公开
    PROCESS FOR PRODUCING MACROLIDE COMPOUND 审中-公开
    生产MACROLIDE化合物的方法

    公开(公告)号：EP1580278A1

    公开(公告)日：2005-09-28

    申请号：EP03775924.8

    申请日：2003-11-27

    申请人： MERCIAN CORPORATION ,  Eisai Co., Ltd.

    发明人： OKUDA, Akifumi ,  YAMAMOTO, Satoshi ,  SAKAI, Takashi ,  TAKEDA, Susumu ,  NAKASHIMA, Takashi ,  KANEKO, Katsura ,  SAMESHIMA, Tomohiro ,  KATO, Taira ,  KAWAMURA, Naoto

    IPC分类号： C12P17/16 ,  C07D407/06 ,  C12N1/20 ,  A61P35/00 ,  A61K31/336

    CPC分类号： C07D407/06 ,  A61K31/336 ,  C12P17/162

    摘要： The present invention provides a novel method of producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation. Starting material which is the 12-membered ringmacrolide compound 11107B represented by the formula (I) is incubated in the presence of a strain belonging to the genus Mortierella, the genus Streptomyces or the family Micromonosporaceae (for example, Streptomyces sp. AB-1704 strain (FERM BP-8551)), each of which has the ability of transforming the 12-membered ring macrolide compound 11107B into a 11107D substance represented by the formula (II), or a preparation of its cultured mycelia and oxygen, and then 11107D substance which is a target material is collected from the treating solution.

    摘要翻译： 本发明提供了一种通过生物转化生产具有抗肿瘤活性的12元环大环内酯化合物11107D的新方法。 在属于被孢霉属，链霉菌属或小单孢菌科（例如链霉菌属AB-1704菌株）的菌株存在下，将由式（I）表示的12-元环大环内酯化合物11107B （FERM BP-8551）），它们各自具有将12元环大环内酯化合物11107B转化为由式（II）表示的11107D物质或其培养的菌丝体和氧的制剂的能力，然后将11107D物质 从处理溶液中收集作为目标物质的物质。

    PREPARATION OF ISOCOUMARIN DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF
    7.
    发明公开
    PREPARATION OF ISOCOUMARIN DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF 审中-公开
    ZWISCHENPRODUKTEFÜRDEREN SYNTHESE的HERSTELLUNG VON ISOCUMARINDERIVATEN

    公开(公告)号：EP1364947A1

    公开(公告)日：2003-11-26

    申请号：EP02710457.9

    申请日：2002-02-01

    申请人： Mercian Corporation

    发明人： NAKATA, Masaya

    IPC分类号： C07D311/76 ,  C07C69/92 ,  C07C67/313 ,  C07C67/343

    CPC分类号： C07D407/12 ,  C07B2200/07 ,  C07C67/307 ,  C07C67/313 ,  C07C67/343 ,  C07C69/92 ,  C07D311/76

    摘要： A method of preparing optically active isocoumarin-3-yl-acetic acid derivatives represented by Formula (I):
    wherein a specific isocoumarin-ketene derivative is subjected to an addition reaction with an optically active alcohol, and then the ester thus obtained is subjected to a hydrolysis reaction. An intermediate for synthesis used therein. A method of preparing isocoumarin-3-yl-acetic acid derivatives represented by Formula (III):
    wherein a specific isocoumarin derivative is subjected to an addition reaction with carbon monoxide and oxygen in the presence of a transition metal catalyst. An intermediate for synthesis used therein.

    摘要翻译： 制备由式（I）表示的光学活性异香豆素-3-基 - 乙酸衍生物的方法：其中特异性异香豆素 - 乙烯酮衍生物与光学活性醇进行加成反应，然后由此获得酯 进行水解反应。 其中使用的合成中间体。 制备由式（III）表示的异香豆素-3-基 - 乙酸衍生物的方法：其中特异性异香豆素衍生物在过渡金属催化剂存在下与一氧化碳和氧进行加成反应。 其中使用的合成中间体。

    NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES
    9.
    发明公开
    NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES 审中-公开
    对于异常与血管并发症合适的芳族酮治疗

    公开(公告)号：EP1081151A1

    公开(公告)日：2001-03-07

    申请号：EP99917219.0

    申请日：1999-04-28

    申请人： MERCIAN CORPORATION ,  Eisai Co., Ltd.

    发明人： WAKABAYASHI, Toshiaki ,  KAWASE, Rena ,  NARUSE, Nobuaki ,  FUJITA, Masanori ,  SAMESHIMA, Tomohiro ,  WATANABE, Yoshio ,  DOBASHI, Kazuyuki ,  FUNAHASHI, Yasuhiro ,  SENBA, Taro

    IPC分类号： C07D493/10 ,  A61K31/35 ,  C12P17/18

    CPC分类号： C07D493/10 ,  C12P17/162

    摘要： The present invention provides a novel bioactive substance having an antiangiogenic effect.
    The chemical compound represented by the formula (1):
    (wherein, R 1 represents hydrogen atom, aldehyde group or a lower acyl group, R 2 and R 3 are the same as or different from each other and represent hydrogen atom or a lower alkoxy group or are combined to represent oxygen atom, R 4 represents a lower alkyl group and R 5 represents hydrogen atom or a lower alkyl group, provided that compounds in which R 1 is aldehyde group, R 2 and R 3 are different from each other and are hydrogen atom or methoxy group, R 4 is ethyl group and R 5 is hydrogen atom are excluded), a salt thereof or a hydrate thereof was isolated from the culture broth of genus Streptomyces and the structure thereof was analyzed.

    摘要翻译： 本发明提供一种具有抗血管生成作用的新的生物活性物质。 由下式表示的化学化合物（1）：（worin，R <1> darstellt氢原子，醛基或低级酰基，R <2>和R <3>是相同的或从每个不同 且表示氢原子或低级烷氧基或被组合以表示氧原子，R <4> darstellt低级烷基且R <5>提供darstellt氢原子或低级烷基，的确在其中化合物中，R <1> 是醛基，R <2>和R <3>是彼此不同的，并且是氢原子或甲氧基，R <4>是乙基且R <5>氢原子的情况除外），其盐或 水合物，从链霉菌属的培养液和分析的其结构隔离。

    CRYSTALLINE ANTHRACYCLINE ANTIBIOTIC AND PROCESS FOR PRODUCING THE SAME
    10.
    发明公开
    CRYSTALLINE ANTHRACYCLINE ANTIBIOTIC AND PROCESS FOR PRODUCING THE SAME 有权
    克氏霉素抗生素在西班牙黑塞哥维那

    公开(公告)号：EP1036797A1

    公开(公告)日：2000-09-20

    申请号：EP98956000.8

    申请日：1998-12-01

    申请人： MERCIAN CORPORATION

    发明人： JOHDO, Osamu ,  NAKAMURA, Kiyotomo ,  YOSHIOKA, Takeo

    IPC分类号： C07H15/252

    CPC分类号： C07H15/252

    摘要： Disclosed are a crystalline form of anthracycline antibiotic having specific characteristic 2θ values as measured by the X-ray diffraction method, and a process for producing the crystalline form. This process comprises the step of crystallization involving the combined use of a specific poor solvent for the antibiotic and a good solvent therefor. This crystalline form has excellent chemical and physical properties.

    摘要翻译： 公开了具有特定特征2和蒽的蒽环类抗生素的结晶形式; 通过X射线衍射法测定的值，以及结晶形态的制造方法。 该方法包括结合使用特定不良溶剂用于抗生素的结晶步骤和用于其的良好溶剂。 该结晶形式具有优异的化学和物理性能。